On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion.
A comparison question rather than a question about one compound.
Two things in the same family get discussed as though the evidence behind them were equivalent, and I do not think it is. One has a trial programme; the other has a mechanism and a following.
What is the fair way to describe the difference without being dismissive about the second?
Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.
Confirming post #2 from a second method, which matters more than confirming it from a second person.
SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.
I looked this up rather than remembered it, which is the right order.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.
That is what I would do. It may not be what is correct.
PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.
On reflection I would soften that slightly.
Clear enough that I do not think I have a follow-up, which is unusual.
Post #5 is the version of this I will quote in future. One addition.
Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.
Where I part company with post #4, and it is a narrow parting.
Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
This follows post #7 rather than contradicting it.
Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.
Worth separating two things that post #8 runs together.
PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.
Anyone who has looked at this more carefully, please correct the record.
Everything in post #7 holds. The case it does not cover is the one I have.
Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.
Not the whole picture, but the part of it I can speak to.
Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.
On analysis of a small molecule: purity by chromatography against a reference standard, identity by mass and by spectroscopy, and residual solvents by a headspace method. That is a much more complete picture than a peptide certificate usually offers.
I read post #11 twice before replying, because I had assumed the opposite.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
I am reporting what happened, not recommending it.
Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.
Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.
Someone should write this up properly, and it should probably not be me.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…
|
+27 | 31 | 17k | 25d |
|
Oral versus injectable exposure: comparing apples to a different fruit
Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Something about oral versus injectable exposure does not reconcile…
|
+19 | 23 | 332 | 8mo |
|
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on…
|
2 | 17k | 6h | |
|
Why oral semaglutide needs an absorption enhancer at all — what changed since
Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since What changes if the standard account of oral semaglutide is wrong? I…
|
2 | 61k | 14mo | |
|
SNAC and the mechanism of oral peptide absorption — the long version
SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. Question about what the published evidence for this…
|
+32 | 36 | 6.8k | 16mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Glucagon receptor…
|
4 | 3.7k | 10mo | |
|
[2026 update] Reading a supplementary appendix and finding the interesting part
On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Collecting what is known about Reading a supplementary appendix in one…
|
+39 | 44 | 8.2k | 5mo |
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…
|
+17 | 21 | 17k | 12d |
|
Why retatrutide discussion here is more cautious than elsewhere — one year on
Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Two things I would like separated before anyone answers on…
|
+92 | 97 | 3.6k | 20h |
|
Why oral semaglutide needs an absorption enhancer at all
Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. Reading back through what has been written here about oral…
|
+59 | 65 | 61k | 7mo |